dorsaVi's UK distributor signs retail pilot deal with Mizuno 
CLICK HERE TO CONTACT dorsaVi

Key points:

  • YourPhysioPlan, dorsaVi’s UK distributor for ViMove, has conducted a retail pilot with sports shoe specialist Mizuno
  • Mizuno used dorsaVi’s ViMove Run in retail stores to better match runners with the ideal running shoe
  • The pilot objectives were to measure the impact of ViMove Run on sales and confirm the viability of the ViMove technology in a retail environment

 

Melbourne, Australia – 28 November 2016: dorsaVi Ltd (ASX: DVL) today announces that leading sports shoe manufacturer Mizuno has used the dorsaVi ViMove Run solution in a pilot program in retail stores in the UK to better understand and inform shoe selection.

The Mizuno Running Solution used the dorsaVi ViMove sensors to wirelessly measure and record movement and the impact of up to nine variables while the customer ran on a treadmill. The assessment was conducted in a matter of minutes providing the retail assistant with analysed results which they could explain to the customer and use to match them with the most appropriate running shoe.

“We felt strongly that there was a natural fit between the rich movement data ViMove delivers and the personalised fit Mizuno are trying to deliver for their running customers”, said Andy Curtis, Co-Founder, YourPhysioPlan.

“The initial results of the pilot are very encouraging – not only is the running assessment with ViMove Run impacting positively on sales in these stores, but also in engaging customers with personalised information which they value. I expect this to further drive brand loyalty,” said Rob Henderson, UK Marketing Manager, Mizuno Corporation UK.

“This is the first retail implementation of our technology and it’s great to see the applicability of the detailed movement analysis data we can provide being used in a completely new way. I expect to see us playing a growing role in the retail sector,” concluded Dr Andrew Ronchi, Chief Executive Officer, dorsaVi.

Key points:

  • YourPhysioPlan, dorsaVi’s UK distributor for ViMove, has conducted a retail pilot with sports shoe specialist Mizuno
  • Mizuno used dorsaVi’s ViMove Run in retail stores to better match runners with the ideal running shoe
  • The pilot objectives were to measure the impact of ViMove Run on sales and confirm the viability of the ViMove technology in a retail environment

 

Melbourne, Australia – 28 November 2016: dorsaVi Ltd (ASX: DVL) today announces that leading sports shoe manufacturer Mizuno has used the dorsaVi ViMove Run solution in a pilot program in retail stores in the UK to better understand and inform shoe selection.

The Mizuno Running Solution used the dorsaVi ViMove sensors to wirelessly measure and record movement and the impact of up to nine variables while the customer ran on a treadmill. The assessment was conducted in a matter of minutes providing the retail assistant with analysed results which they could explain to the customer and use to match them with the most appropriate running shoe.

“We felt strongly that there was a natural fit between the rich movement data ViMove delivers and the personalised fit Mizuno are trying to deliver for their running customers”, said Andy Curtis, Co-Founder, YourPhysioPlan.

“The initial results of the pilot are very encouraging – not only is the running assessment with ViMove Run impacting positively on sales in these stores, but also in engaging customers with personalised information which they value. I expect this to further drive brand loyalty,” said Rob Henderson, UK Marketing Manager, Mizuno Corporation UK.

“This is the first retail implementation of our technology and it’s great to see the applicability of the detailed movement analysis data we can provide being used in a completely new way. I expect to see us playing a growing role in the retail sector,” concluded Dr Andrew Ronchi, Chief Executive Officer, dorsaVi.

Request more information about dorsaVi

CONTACT ME FOR MORE INFORMATION

Randomised Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.

Recent news: What's happening at dorsaVi 

ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury

Fix the following errors:
Hide